Hims Hers closes up 10 percent as Lilly tirzepatide compounding dispute resolution delayed
| PHPSX Fund | USD 21.21 0.10 0.47% |
Slightly above 62% of Pharmaceuticals Ultrasector's investor base is looking to short. The analysis of overall sentiment of trading Pharmaceuticals Ultrasector Profund mutual fund suggests that many investors are alarmed at this time. Pharmaceuticals Ultrasector's investing sentiment can be driven by a variety of factors including economic data, Pharmaceuticals Ultrasector's earnings reports, geopolitical events, and overall market trends.
Pharmaceuticals |
HIM Hers Health stock rises after federal court closes case on FDAs GLP-1 tirzepatide shortage determination. Read more here.
Read at seekingalpha.com
 |
Pharmaceuticals Ultrasector Fundamental Analysis
We analyze Pharmaceuticals Ultrasector's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharmaceuticals Ultrasector using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharmaceuticals Ultrasector based on its fundamental data. In general, a quantitative approach, as applied to this mutual fund, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Three Year Return
Three Year Return Comparative Analysis
Pharmaceuticals Ultrasector is currently under evaluation in three year return among similar funds. Tree Year Return shows the total annualized return generated from holding a fund or ETFs for the last three years. The return measure includes capital appreciation, losses, dividends paid, and all capital gains distributions. This return indicator is considered by many investors to be solid measures of fund mid-term performance.
Pharmaceuticals Ultrasector Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Pharmaceuticals Ultrasector mutual fund to make a market-neutral strategy. Peer analysis of Pharmaceuticals Ultrasector could also be used in its relative valuation, which is a method of valuing Pharmaceuticals Ultrasector by comparing valuation metrics with similar companies.
Peers
Pharmaceuticals Ultrasector Related Equities
| SHSSX | Blackrock Health | 0.03 | ||||
| BGHDX | Baillie Gifford | 0.00 | ||||
| SCHLX | Deutsche Health | 0.34 | ||||
| BHCHX | Baron Health | 0.41 | ||||
| HIAHX | Hartford Healthcare | 0.47 | ||||
| LHCCX | Lord Abbett | 1.12 |
Other Information on Investing in Pharmaceuticals Mutual Fund
Pharmaceuticals Ultrasector financial ratios help investors to determine whether Pharmaceuticals Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pharmaceuticals with respect to the benefits of owning Pharmaceuticals Ultrasector security.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |